Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SLC5A2 | P31639 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | FABP7 | O15540 | 1/20 | 0.35 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6860725 | 1.00 | TSHR (0.54) | TSHREPHX1CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL3350751 | 0.89 | TSHR (0.54) | TSHREPHX1CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL6860722 | 0.89 | TSHR (0.54) | TSHREPHX1CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL5956359 | 0.86 | TSHR (0.71) | TSHREPHX1CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL29010567 | 0.83 | TSHR (0.52) | TSHREPHX1CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL29010564 | 0.83 | TSHR (0.52) | TSHREPHX1CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL8943453 | 0.82 | TSHR (0.48) | TSHREPHX1CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL6534627 | 0.80 | TSHR (0.53) | TSHREPHX1CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL27924060 | 0.80 | TSHR (0.53) | TSHREPHX1CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL29010566 | 0.80 | TSHR (0.51) | TSHREPHX1CYP2C9CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015188060-A1 | FLUOROSULFONYL sEH INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-12-10 | — | — | WO | disclosed |
| WO-2010053829-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | ARETE THERAPEUTICS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| EP-2132176-A1 | 4-PIPERIDINYLUREA COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Arete Therapeutics, Inc. (US) | 2009-12-16 | — | — | EP | disclosed |
| EP-2124917-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | Arete Therapeutics, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20090270382-A1 | Soluble epoxide hydrolase inhibitors | ARETE THERAPEUTICS, INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2009129508-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2009-10-22 | — | — | WO | disclosed |
| US-20090197916-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | ARETE THERAPEUTICS, INC | 2009-08-06 | — | — | US | disclosed |
| EP-2081898-A2 | ADAMANTYLUREA COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Arete Therapeutics, INC. (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-2079695-A2 | PHENYLUREA COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Arete Therapeutics, INC. (US) | 2009-07-22 | — | — | EP | disclosed |
| EP-2077839-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | Arete Therapeutics, INC. (US) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008039999-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008039794-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008040000-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20080076770-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-03-27 | — | — | US | disclosed |
| WO-2008016884-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-02-07 | — | — | WO | disclosed |
| US-20080032978-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-02-07 | — | — | US | disclosed |
| US-6794158-B2 | FLUORESCENT PROBE FOR USE AS DIAGNOSTIC TOOL IN MONITORING PREFERENTIAL ENZYME ACTIVITY | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-09-21 | — | — | US | disclosed |
| US-20030082665-A1 | Fluorescence polarization assay | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-05-01 | — | — | US | disclosed |
| WO-2002082082-A2 | FLUORESCENCE POLARIZATION ASSAY | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2000023060-A2 | METHOD OF TREATING IMMUNOLOGICAL DISORDERS MEDIATED BY T-LYMPHOCYTES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270382-A1 | Soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, LTA4H | TSHR 1647/4885EPHX1 1/4885CYP2C9 340/4885 |
| US-20080076770-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | TSHR 2218/4885EPHX1 1/4885CYP2C9 288/4885 |
| US-20090197916-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | EPHX1, NCEH1, PNLIP | TSHR 2459/4885EPHX1 1/4885CYP2C9 1079/4885 |
| US-20030082665-A1 | Fluorescence polarization assay | EPHX1, EPHX2, LTA4H | TSHR 3053/4885EPHX1 1/4885CYP2C9 609/4885 |
| US-20080032978-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | TSHR 2234/4885EPHX1 1/4885CYP2C9 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.